Skip to main
OTLK
OTLK logo

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc has demonstrated substantial investment in its growth, with general and administrative expenses rising 106.2% year-over-year to $11.9 million, reflecting the company's commitment to scaling operations. The ongoing success of the ONS-5010 program, particularly indicated by noninferiority results to ranibizumab in the NORSE EIGHT trial, positions the product favorably in a competitive market and may enhance future revenue prospects. Furthermore, strategic collaborations, such as the partnership with Cencora for commercial launch support, signify potential for expanded market reach and operational sustainability, reinforcing a positive outlook for the company's financial trajectory.

Bears say

Outlook Therapeutics Inc. reported a significant financial setback in 1Q24, with a loss per share of $0.78 and a widening operating loss of $21.6 million, which exceeded earlier estimates. The company’s failure to meet the pre-specified non-inferiority endpoint in the NORSE EIGHT clinical study raises concerns about the viability of ONS-5010, further compounded by the potential for regulatory hurdles that could delay its approval. Additionally, the adjustment of the EV/Sales multiple from 7.5x to 3.5x and the resultant reduction in price target indicate a deteriorating financial outlook and potential for further share dilution through equity financing.

OTLK has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 10 analysts, OTLK has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.